Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose

Chinese Journal of Medical Genetics

Volumn 28, Issue 6, 2011, Pages 661-665

  Huang, Sheng Wen ^a   Xiang, Dao Kang ^a   Wu, Hai Li ^a   Chen, Bao Lin ^a   An, Bang Quan ^a   Li, Gut Fang ^a  

^a GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Genetic factor; Personalized medicine; Pharmacogenetics; Warfarin

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME P450 2C9; EPOXIDE HYDROLASE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AGE; ALGORITHM; ARTICLE; BODY WEIGHT; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTICOAGULANTS; APOLIPOPROTEINS E; ARYL HYDROCARBON HYDROXYLASES; CARBON-CARBON LIGASES; EPOXIDE HYDROLASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN; YOUNG ADULT;

EID: 84855286929     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1003-9406.2011.06.014     Document Type: Article

References (19)

1. Yu HC, Chan TY, Critchely JA, et al. Factors determining the maintenance dose of warfarin in Chinese patients. QJM, 1996, 89:127-135. (Pubitemid 26053126)
2. Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatment with warfarin in Chinese population. Ann Pharmacother, 2000, 34:1395-1401.
3. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J, 2003, 3:202-214. (Pubitemid 37167925)
4. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719. (Pubitemid 29103806)
5. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005, 106:2329-2933.
6. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics, 2009, 19:226-234.
7. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005, 352:2285-2293. (Pubitemid 40740552)
8. Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta, 2004, 348:57-61. (Pubitemid 39209001)
9. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J, 2005, 5:262-270. (Pubitemid 41131718)
10. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet, 2007, 121:23-34. (Pubitemid 46421137)
11. Sconce EA, Daly AK, Khan TI, et al. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics, 2006, 16:609-611. (Pubitemid 44100205)
12. Huang SW, Xiang DK, An BQ, et al. Detection of apolipoprotein E genotype by denaturing high performance liquid chromatography and polymerase chain reaction. Chin J Clin Lab Sci, 2011, 29:40-42.
13. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J, 2007, 7:99-111. (Pubitemid 46567142)
14. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 2005, 106:135-140. (Pubitemid 40967184)
15. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the doseanticoagulant effect of warfarin. Blood, 2005, 105:645-649. (Pubitemid 40070748)
16. Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol, 2007, 63:1135-1141. (Pubitemid 350112769)
17. Veenstra DL, You JH, Rieder MJ, et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics, 2005, 15:687-691. (Pubitemid 41345320)
18. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther, 2006, 79:291-302.
19. Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther, 2006, 79:197-205.